Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy

Related Experiment Video

Updated: Aug 7, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Yin-Hsiu Chien1, Ni-Chung Lee, Shinn-Forng Peng

  • 1Department of Pediatrics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan.

Pediatric Research
|July 22, 2006
PubMed

Insights

Pompe disease, a genetic disorder, often involves brain development issues. Enzyme replacement therapy (ERT) may improve brain myelination in infants with Pompe disease, but further research is needed.

Area of Science:

  • Neurology
  • Genetics
  • Biochemistry

Background:

  • Pompe disease primarily affects muscles and heart, but brain involvement in infantile cases is unclear.
  • Glycogen accumulation occurs in the nervous system, yet its significance in infantile-onset Pompe disease remains poorly understood.
  • Enzyme replacement therapy (ERT) has prolonged survival in some infantile Pompe disease patients.

Purpose of the Study:

  • To investigate brain development, specifically myelination, in infantile-onset Pompe disease patients undergoing ERT.
  • To assess the impact of ERT on neurological outcomes in this patient population.
  • To correlate MRI and MRS findings with treatment response.

Main Methods:

  • Utilized brain magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) to study five infantile-onset Pompe disease cases.
  • Monitored myelination milestones and ventricular size before and after ERT initiation.
  • Evaluated neurological progression in relation to ERT efficacy in muscle tissue.

Main Results:

  • All patients exhibited delayed myelination milestones at the start of ERT.
  • Four out of five patients showed improved myelination following ERT, with some persistent ventricular dilatation.
  • One patient unresponsive to ERT displayed slow myelination and signs of neuronal and myelination loss.

Conclusions:

  • Myelination defects are a common feature of infantile-onset Pompe disease.
  • Effective ERT may lead to improvements in brain myelination in surviving patients.
  • The direct therapeutic effect of ERT on the brain requires further investigation.

More Related Videos

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...